Fluicell AB is a Sweden-based company within healthcare industry. It commercializes a product portfolio for processing and studying of individual cells, primarily in the field of drug development. The Companyâ€™s products comprise research tools BioPen and Dynaflow Resolve. Tools enable researchers to study, process and measure drug impact on individual cells. Also, the Company develops bioprinting technology Biopixlar Retina in both two-dimensional (2D) and three-dimensional (3D) options. Biopixlar Retina creates complex tissue-like structures with control over positioning of individual cells.

Employees

Sector

Biotechnology & Medical Research

Calendar

08-21 Earnings release - Q2 2026

More about the company

Quotes

Date	Price	Change	Volume
17/08/26	SEK 29.10	-2.68%	2,208
14/08/26	SEK 29.90	+2.40%	3,716
13/08/26	SEK 29.20	0.00%	466
12/08/26	SEK 29.20	-3.63%	4,121
11/08/26	SEK 30.30	-0.98%	2,190

Delayed Quote Nasdaq Stockholm

More quotes

Income Statement and Estimates

More financial data

Select your edition

All financial news and data tailored to specific country editions

NORTH AMERICA

United-States

Canada

Market Closed - Nasdaq Stockholm 19:00:00 17/08/2026 +03			5-day change	1st Jan Change
29.10 ^SEK	-2.68%		-3.00%	+191.00%

05-08	Fluicell reports sharp revenue surge and swings to profit in the first quarter	FW
05-08	Fluicell Q1 net sales up at SEK 6.1 million	RE

Market Cap	39.97M 4.21M 3.63M 3.41M 3.11M 5.84M 403M 5.92M 15.66M 202M 15.81M 15.47M 671M	P/E 2024	-1.1x	P/E 2025	-1.65x
Enterprise Value	37.71M 3.97M 3.43M 3.22M 2.93M 5.51M 380M 5.59M 14.78M 190M 14.91M 14.59M 633M	EV / Sales 2024	0.71x	EV / Sales 2025	0.75x
Free-Float	75.27%	Yield 2024 *	-	Yield 2025	-

05-08	Fluicell reports sharp revenue surge and swings to profit in the first quarter	FW
05-08	Fluicell Q1 net sales up at SEK 6.1 million	RE
05-08	Fluicell AB Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
05-07	Fluicell nominates AstraZeneca executive to Board of Directors	FW
04-30	Committee proposes Niklas Frisk as Fluicell chairman	RE
04-30	Fluicell proposes new Board of Directors	FW
02-20	Fluicell Narrows Operating Loss in Q4, Final Report Confirms	FW
02-20	Fluicell Q4 net sales SEK 3.8 mln	RE
02-20	Fluicell AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025	CI
02-11	Fluicell gets EPO approval for microfluidics patent	RE
02-11	Fluicell Granted EU Patent for Microfluidics Technology	FW
02-06	Fluicell Reports Significant Improvement in Q4 - Preliminary Figures	FW
12-12	Fluicell receives upfront payment of 1.5 million in collaboration with Ambusol	FW

02/09/25	Fluicell : and Ambusol enter into exclusive global license and development agreement regarding technology for cancer treatment	PU
22/08/25	Fluicell : receives funding from Breakthrough T1D for collaboration with leading medical university to develop tissue-based type 1 diabetes therapeutics	PU
29/09/21	BioStock: Fluicell partners with big pharma for 3-D bioprinting project	AQ
01/07/21	BioStock: 2021 represents beginning of new era for Fluicell	AQ
18/05/21	BioStock: Fluicell dives into regenerative medicine field	AQ

Fluicell AB Stock

Stocks

FLUI

SE0023595459

Biotechnology & Medical Research

Valuation: Fluicell AB

Chart: Fluicell AB

Latest news : Fluicell AB

Press Releases: Fluicell AB

Quotes and Performance

Course Extremes

Managers and Directors: Fluicell AB

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Income Statement and Estimates

1 day	-2.68%
1 week	-3.00%
Current month	-6.43%
1 month	-16.62%
3 months	-14.91%
6 months	+216.30%
Current year	+191.00%

1 week	28.5	30.7
1 month	27.6	32.7
Current year	7.65	67.2
1 year	7.65	67.2
3 years	7.45	594.3
5 years	7.45	12,145
10 years	7.45	15,330

Manager	Title	Age	Since
Carolina Trkulja CEO	Chief Executive Officer	42	01/01/2023
Gavin Jeffries CTO	Chief Tech/Sci/R&D Officer	46	01/01/2017
Niklas Joakim Wahlberg DFI	Director of Finance/CFO	56	01/07/2023

Director	Title	Age	Since
Daniel T. Chiu BRD	Director/Board Member	54	01/01/2017
Carl Fhager BRD	Director/Board Member	51	01/01/2017
Jan Orwar BRD	Director/Board Member	62	01/01/2015

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
FLUICELL AB	-2.68%	-3.00%	+169.44%	-93.87%	4.32M
LONZA GROUP AG	+0.68%	-2.28%	+2.16%	+19.70%	48.42B
REVOLUTION MEDICINES, INC.	+4.07%	+2.43%	+483.70%	+623.80%	43.66B
BEONE MEDICINES AG	+4.33%	+0.98%	+12.80%	+88.53%	39.51B
IQVIA HOLDINGS INC.	+1.94%	-0.31%	+26.24%	+12.62%	38.95B
CELLTRION, INC.	-0.50%	+0.85%	+20.60%	+58.18%	32.61B
ASCENDIS PHARMA A/S	-0.44%	-3.22%	-	-	16.32B
MEDPACE HOLDINGS, INC.	+3.22%	-0.88%	+30.42%	+135.47%	16.15B
EUROFINS SCIENTIFIC SE	-0.62%	-0.06%	+3.46%	+27.74%	14.16B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	+2.35%	+3.48%	+82.95%	+43.41%	13.37B
Average	+1.23%	-0.01%	+92.42%	+101.73%	26.31B
Weighted average by Cap.	+1.93%	+0.04%	+101.59%	+150.86%

	2024	2025
Net sales	5.35M 563K 486K 456K 416K 781K 53.87M 792K 2.1M 26.99M 2.12M 2.07M 89.77M	15.22M 1.6M 1.38M 1.3M 1.18M 2.22M 153M 2.25M 5.96M 76.79M 6.02M 5.89M 255M
Net income	-15.51M -1.63M -1.41M -1.32M -1.21M -2.27M -156M -2.3M -6.08M -78.26M -6.13M -6M -260M	-8.33M -878K -758K -711K -647K -1.22M -83.91M -1.23M -3.27M -42.04M -3.29M -3.22M -140M
Net Debt	-15.92M -1.68M -1.45M -1.36M -1.24M -2.33M -160M -2.36M -6.24M -80.34M -6.3M -6.16M -267M	-2.26M -238K -206K -193K -176K -330K -22.78M -335K -886K -11.41M -894K -875K -37.96M